There is growing evidence that MR antagonists have benefits in other ocular diseases, attenuating vascular leakage and oedema in central serous chorioretinopathy (CSCR), a condition affecting the outer retina and BRB [52]. The gene discussed is NR3C2; the disease is central serous retinopathy.